Molecular mechanism and inhibitor development of platelet-dependent tumor growth progression in hematogenous metastasis
| Project/Area Number |
23701107
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Clinical oncology
|
|---|
| Research Institution | Japanese Foundation For Cancer Research |
|---|
Principal Investigator |
TAKAGI Satoshi 公益財団法人がん研究会, がん化学療法センター基礎研究部, 研究員 (20582240)
|
|---|
| Project Period (FY) |
2011 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2012: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2011: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | がん / 血行性転移 / 血小板 |
|---|
| Research Abstract |
The purpose of this study is to clarify the signal transduction pathways in cancer cells activated by interaction with platelets and to develop inhibitors against these signaling pathways. I found that direct interaction of platelets and sarcoma cells contributes to tumor malignancy by enhancing both tumor growth and tumor drug resistance, and identified PI3K-Akt pathway as a key signal transduction pathway which causes platelet-mediated tumor malignancy. Furthermore, sarcoma cell-induced platelet aggregation is dependent on platelet-aggregation inducing factor Aggrus, suggesting that anti-Aggrus neutralizing antibodies would be useful as hematogenous metastasis inhibitors against some types of cancers
|
Report
(3 results)
Research Products
(21 results)
